Affimed–Leucadia: investor conference, 201711 supply service Affimed presents at Jefferies 2017 London Healthcare Conference

	Period	2017-11-15
	Region	London, Greater London
	Country	United Kingdom (GB)
	Partner, 1st	Affimed N.V. (Nasdaq: AFMD)
	Group	Affimed (Group)
	Partner, 2nd	Jefferies (Group)
	Today	Leucadia (Group)
	Group	Leucadia (Group)
	Product	Jefferies 2017 London Healthcare Conference
	Product 2	cancer immunotherapy (immuno-oncology, I-O)
	Person	Hoess, Adi (Affimed 201109– CEO before CCO before Jenowis + Jerini 2003– + Carl Zeiss AG + MorphoSys AG)
	Person 2	Ammon (formerly Alexandru), Anca (Ammon Communications 202103 before MorphoSys + Affimed + MacDougall European Office)

Affimed N.V.. (11/15/17). "Press Release: Affimed to Present at the Jefferies 2017 London Healthcare Conference". Heidelberg.

Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies, announced today that Dr. Adi Hoess, CEO, will present at the Jefferies 2017 London Healthcare Conference on Wednesday, November 15, 2017, at 4:00 pm GMT.

A live webcast of the conference presentation can be accessed through the “Events” section on the “Investors & Media” page of the Affimed website at www.affimed.com/events.php. A replay of the presentation will be available from Affimed’s website for 30 days following the conference.

About Affimed N.V.

Affimed (Nasdaq: AFMD) engineers targeted immunotherapies, seeking to cure patients by harnessing the power of innate and adaptive immunity (NK and T cells). We are developing single and combination therapies to treat cancers and other life-threatening diseases. For more information, please visit www.affimed.com.

Contact:

Anca Alexandru, Head of Communications, EU IR
Phone: +49 6221 64793341
E-Mail: a.alexandru@affimed.com, IR@affimed.com